Dr. Alison Ehrlich, MD
Dermatology (Dermatology Physician)
Medicare and federal program status
Opted out of Medicare from September 30, 2019 through September 30, 2027. Medicare does not pay for this clinician’s services: patients with Medicare sign a private contract and pay the clinician directly. They can still order tests and refer Medicare patients to other providers.
Source: CMS Medicare Opt Out Affidavits (record last updated October 21, 2026). Opting out is a legal choice many clinicians make, often to run a cash or concierge practice.
At a glance
- Medical school
- George Washington University School of Medicine (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2005
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: George Washington University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
MD license D0055828 -
Procedural Dermatology Physician
MD license D0055828
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Fluocinonide Other prescribers in Chevy Chase, MD | 31 |
| Dupixent Pen (dupilumab) Other prescribers in Chevy Chase, MD | 16 |
| Tremfya (guselkumab) | 11 |
| Ketoconazole Other prescribers in Chevy Chase, MD | 11 |
| Metronidazole Other prescribers in Chevy Chase, MD | 11 |
| Triamcinolone Acetonide Other prescribers in Chevy Chase, MD | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 10 payments worth $213 in total to this clinician.
| Galderma Laboratories, L.P. | $66.28 |
|---|---|
| AbbVie Inc. | $55.06 |
| Amgen Inc. | $53.02 |
| Biofrontera Inc. | $20.14 |
| Verrica Pharmaceuticals Inc. | $18.88 |
| Food and Beverage | $213 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $44,066 in research payments for these studies, mostly to the institutions running them.
- Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Sanofi US Services Inc. · Recruiting · NCT05263206 - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.